Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening.

LUNSUMIO may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with LUNSUMIO and can also be severe or life-threatening.

Genentech, a member of the Roche Group, announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody program, including eight oral presentations, were presented at the 65th ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered ...

In-depth LUNSUMIO Market Assessment This report provides a detailed market assessment of LUNSUMIO for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 ...

Lunsumio can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with Lunsumio.

F. Hoffmann-La Roche Ltd. Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas 1,2. New data ...

Lunsumio’s overall CRS rate is much lower at 39%, including 2.5% of grade 3 or above. Between Lunsumio and Columvi, Roche has directed Lunsumio at FL—instead of the more aggressive DLBCL ...

Roche’s Lunsumio could soon become the first bispecific to join the U.S. treatment armamentarium for non-Hodgkin lymphoma.. Wednesday, Roche said the FDA has put its application for Lunsumio ...

Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in ...

– With Lunsumio, people with heavily pretreated follicular lymphoma (FL) may experience remission with a chemotherapy-free, fixed-duration treatment that can be accessed in an outpatient setting – ...

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "LUNSUMIO Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides ...